aTYR PHARMA INC Net Income (Loss) Available to Common Stockholders, Basic
aTYR PHARMA INC (ATYR) reported Net Income (Loss) Available to Common Stockholders, Basic of -$48.21 million for the 12-month period ending 2017-12-31, per its 10-K filed 2018-03-20.
Discontinued › Income Statement
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2018-03-20
- aTYR PHARMA INC net income (loss) available to common stockholders, basic for the quarter ending 2016-12-31 was -$12.57M.
- aTYR PHARMA INC net income (loss) available to common stockholders, basic for the quarter ending 2016-09-30 was -$13.82M.
- aTYR PHARMA INC net income (loss) available to common stockholders, basic for the quarter ending 2016-06-30 was -$15.38M.
- aTYR PHARMA INC net income (loss) available to common stockholders, basic for the quarter ending 2015-12-31 was -$16.49M.
- aTYR PHARMA INC net income (loss) available to common stockholders, basic for fiscal 2017 was -$48.21M.
- aTYR PHARMA INC net income (loss) available to common stockholders, basic for fiscal 2016 was -$57.85M.
- aTYR PHARMA INC net income (loss) available to common stockholders, basic for fiscal 2015 was -$47.99M.
- aTYR PHARMA INC net income (loss) available to common stockholders, basic for fiscal 2014 was -$24.77M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month |
|---|---|---|---|---|
| 2017-12-31 | -$48.21M 10-K · filed 2018-03-20 | |||
| 2016-12-31 | -$12.57M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-20 | -$26.39M derived: sum of 2 quarters · filed 2018-03-20 | -$41.77M derived: sum of 3 quarters · filed 2018-03-20 | -$57.85M 10-K · filed 2018-03-20 |
| 2016-09-30 | -$13.82M 10-Q · filed 2016-11-14 | -$29.20M derived: sum of 2 quarters · filed 2016-11-14 | -$45.29M 10-Q · filed 2016-11-14 | |
| 2016-06-30 | -$15.38M 10-Q · filed 2016-08-10 | -$31.47M 10-Q · filed 2016-08-10 | ||
| 2015-12-31 | -$16.49M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-20 | -$27.82M derived: sum of 2 quarters · filed 2018-03-20 | -$38.92M derived: sum of 3 quarters · filed 2018-03-20 | -$47.99M 10-K · filed 2018-03-20 |
| 2015-09-30 | -$11.33M 10-Q · filed 2016-11-14 | -$22.42M derived: sum of 2 quarters · filed 2016-11-14 | -$31.50M 10-Q · filed 2016-11-14 | -$37.53M derived: sum of 4 quarters · filed 2017-03-16 |
| 2015-06-30 | -$11.10M 10-Q · filed 2016-08-10 | -$20.17M 10-Q · filed 2016-08-10 | -$26.20M derived: sum of 3 quarters · filed 2017-03-16 | -$32.97M derived: sum of 4 quarters · filed 2017-03-16 |
| 2015-03-31 | -$9.07M 10-Q · filed 2015-06-18 | -$15.11M derived: sum of 2 quarters · filed 2017-03-16 | -$21.88M derived: sum of 3 quarters · filed 2017-03-16 | -$27.61M derived: sum of 4 quarters · filed 2017-03-16 |
| 2014-12-31 | -$6.04M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | -$12.81M derived: sum of 2 quarters · filed 2017-03-16 | -$18.54M derived: sum of 3 quarters · filed 2017-03-16 | -$24.77M 10-K · filed 2017-03-16 |
| 2014-09-30 | -$6.77M 10-Q · filed 2015-11-10 | -$12.50M derived: sum of 2 quarters · filed 2015-11-10 | -$18.73M 10-Q · filed 2015-11-10 | |
| 2014-06-30 | -$5.73M 10-Q · filed 2015-08-12 | -$11.96M 10-Q · filed 2015-08-12 | ||
| 2014-03-31 | -$6.23M 10-Q · filed 2015-06-18 | |||
| 2013-12-31 | -$21.65M 10-K · filed 2016-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B |